Clinical Research, Pharma & Healthcare Financing

Jacobio’s IND Accepted for Phase I/II Trial of BET Inhibitor JAB-8263

Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263’s IND application is expected to be completed within 30 working days

Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: “Autoimmune diseases affect 5%-9% of the global population. Currently, the majority of therapies are monoclonal antibodies administered intravenously, with only a few oral drugs approved. Through our internal translation research and discovery efforts, we intend to expand the therapeutic value of our BET inhibitor from oncology to autoimmune diseases, ultimately benefiting a broader patient population.”

Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.

Related posts

Scienture Draws on ELOC, Suspends Further Draws for 30 Days

GlobeNewswire

Orbis Medicines Appoints Mikael Dolsten as Board Chair

Business Wire

AN2 Therapeutics Shares Phase 3 EBO-301 Data and Future Milestones

Business Wire